On October 25, 2017 Synthetic Biologics, Inc. (NYSE American: SYN), a late-stage clinical company developing therapeutics that preserve the microbiome to protect and restore the health of patients, announced reported that the Company intends to release its operational highlights and financial results for the quarter ended September 30, 2017 on Wednesday, November 1, 2017, and to host a conference call the same day at 4:30 p.m. EDT(Press release, Synthetic Biologics, OCT 25, 2017, View Source [SID1234521177]). The dial-in information for the call is as follows:

U.S. (toll free): 1-888-347-5280
International: +1 412-902-4280

Participants are asked to dial in 15 minutes before the start of the call to register. The call will also be webcast over the Internet at View Source." target="_blank" title="View Source." rel="nofollow">View Source An archived replay of the call will be available for approximately ninety (90) days at the same URL, View Source, beginning approximately one hour after the call’s conclusion.

On October 25, 2017 Conatus Pharmaceuticals Inc. (Nasdaq:CNAT) reported that it will report financial results for the third quarter ended September 30, 2017, after the market close on Wednesday, November 1, 2017 (Press release, Conatus Pharmaceuticals, OCT 25, 2017, View Source [SID1234521178]). Conatus will host a conference call and audio webcast at 4:30 p.m. Eastern Time on Wednesday, November 1, 2017, to discuss the financial results and provide a corporate update.

To access the conference call, please dial 877-312-5857 (domestic) or 970-315-0455 (international) at least five minutes prior to the start time and refer to conference ID 99505370. A live and archived audio webcast of the call will also be available in the Investors section of the Conatus website at www.conatuspharma.com.

On October 25, 2017 Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, reported that it will release its third quarter 2017 financial results on Thursday, November 2, 2017 (Press release, Insmed, OCT 25, 2017, View Source [SID1234521153]).

Insmed management will host a conference call for investors beginning at 8:30 a.m. ET on Thursday, November 2, 2017 to discuss the financial results and provide a business update.

Shareholders and other interested parties may participate in the conference call by dialing (844) 707-0669 (domestic) or (703) 639-1223 (international) and referencing conference ID number 5699819. The call will also be webcast live on the internet on the company’s website at www.insmed.com.

A replay of the conference call will be accessible approximately two hours after its completion through November 9, 2017 by dialing (855) 859-2056 (domestic) or (404) 537-3406 (international) and referencing conference ID number 5699819. A webcast of the call will also be archived for 90 days under the Investor Relations section of the company’s website at www.insmed.com.

On October 25, 2017 Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, reported that it will report its third quarter 2017 financial and operating results after the close of the U.S. financial markets on Tuesday, October 31, 2017 (Press release, Iovance Biotherapeutics, OCT 25, 2017, View Source [SID1234521140]). Management will host a conference call and live audio webcast to discuss these results and provide a corporate update at 4:30 p.m. ET.

In order to participate in the conference call, please dial 1-844-646-4465 (domestic) or 1-615-247-0257 (international) and reference the access code 1423064. The live webcast can be accessed under “News & Events” in the “Investors” section of the Company’s website at View Source or you may use the link: View Source

A replay of the call will be available from October 31, 2017 at 7:00 p.m. ET to November 30, 2017 at 8:30 p.m. ET. To access the replay, please dial 1-855-859-2056 (domestic) or 1-404-537-3406 (international) and reference the access code 1423064. The archived webcast will be available for thirty days in the Investors section of Iovance Biotherapeutics’ website at View Source.